HD 101
CME- HD 101
Course description:
TO RECEIVE ACCME CREDITS FOR THESE ACTIVITIES, you must complete the HDSA registration, the self-assessment, view the recorded lecture and complete the post assessment and evaluation. Each successfully completed activity provides one CME credit.
Purpose Statement:
These online CME activities are designed to offer expert knowledge about Huntington’s disease (HD) to primary care providers and family practitioners who provide care to people with HD at the local level. They also target neurologists and psychiatrists who are not familiar with HD. The activity will cover the natural history of the disease, genetics of HD, the psychiatric, neuropsychological and motor symptoms of the disease with treatment options, Juvenile onset HD, assembling a team based care team, research and clinical trials for people with HD and documenting disability for a person with HD.
Target Audience: The target audience for this self-study CME activity is primary care providers, family physicians, general neurologists, and neurology residents.
WE MOVE Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of WE MOVE and the Huntington’s Disease Society of America (HDSA). WE MOVE is accredited by the ACCME to provide continuing medical education to physicians.
Credit Designation: WE MOVE designates each activity for a maximum of 1.00 hour(s) AMA PRA™ Category 1 Credit. Each physician/learner should claim only those credits that he/she actually spent in the activity.
Off-label Disclosure: These educational activities includes discussion of the off-label use of some medications.
Technical Requirements:
The following hardware/software specifications must be met or exceeded to complete these activities:
Web Browser and Internet connection
Free Flash plug-in version 8 or higher
Computer equipped with audio output (speakers or headphones)
Printer
Pop-up windows enabled for viewing support materials
Instructions for Participants:
There is no fee charged for participation in this CME activity.
Read the target audience, purpose statement, and author disclosures on this screen.
Study the educational activity as presented on this web site.
Read, complete, and submit answers to the Review Questions and complete the Evaluation Form. These documents are available on the last screen of this CME activity.
Print CME certificate.
Additional Resources: Huntington’s Disease society of America (HDSA): www.hdsa.org
WE MOVE: www.wemove.org, Huntington Study Group: www.huntington-study-group.org, clinical trials: www.clinicaltrials.gov
Faculty Information and Disclosure:
WE MOVE requires that faculty participating in CME activity disclose any relationship that might pose a potential, apparent, or real conflict of interest. The authors of this CME activity indicated that there were the following relationships to disclose. The authors and reviewers received an honorarium for their participation in this CME activity.
Kevin Biglan, MD: Disclosures will appear on presentation
Thomas Bird, MD: Licensing fees and Speaker’s Bureau for Athena Diagnostics
Samuel Frank, MD: Research and consulting fees from Lundbeck, Inc.
Martha Nance, MD: Research support grant from Medivation and NeuroSearch; Spouse on Speakers Bureau for Roche and Genentech
Jane Paulsen, PhD: Support from National Institutes of Health (NIH), National Institute for Neurological Disorders and Stroke (NINDS – NS40068 and NS054893), the Huntington’s Disease Society of America and CHDI Foundation, Inc.
Adam Rosenblatt, MD: Consultant for Lundbeck, Inc.
Vicki Wheelock, MD: Honorarium for A Physicians Guide to the Management of Huntington’s Disease (Third edition), educational grant from Lundbeck, Inc.
Funding Statement: HDSA and WE MOVE gratefully acknowledge an unrestricted educational grant from Lundbeck, Inc. and the Griffin Foundation through which we are able to produce this activity.
Disclaimer: The material presented here does not necessarily reflect the views of the Huntington’s Disease Society of America (HDSA) or WE MOVE, Inc. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Learning Objectives: After completing this self-directed study, the participant should be able to:
- Understand the diagnostic criteria and current neurologic management of Huntington’s disease. (ABMS/ACGME Competencies: Medical Knowledge, Patient Care)
- Understand the psychiatric manifestations of HD and their treatment.
(ABMS/ACGME Competencies: Medical Knowledge, Patient Care) - Gain awareness of cognitive features of HD and the role of neuropsychological assessment. (ABMS/ACGME Competencies: Medical Knowledge, Patient Care)
- Understand the benefits, limitations, and ethical issues of genetic testing in HD. (ABMS/ACGME Competencies: Medical Knowledge, Patient Care)
- Appreciate the role of the multidisciplinary team in the management of HD including long-term care. (ABMS/ACGME Competencies: Medical Knowledge, Patient Care)
- Acquire knowledge and understanding of prevalence and diagnostic procedures utilized for juvenile form of the disease. (ABMS/ACGME Competencies: Medical Knowledge, Patient Care)
- Expand understanding of unique issues pertaining to quality of life in HD. (ABMS/ACGME Competency: Patient Care)
- Increase knowledge of resources to connect HD patients and families with clinical research opportunities in their geographic areas. (ABMS/ACGME Competency: Patient Care)
|
Activity |
Title |
Instructor |
Enter Module |
|
Activity 1 |
Natural History of HD and Introduction to Series- Explores the stages and progression of Huntington’s Disease |
Samuel Frank, MD |
|
|
Activity 2 |
Genetic Factors in HD- Will address hereditary, CAG repeat and what it means as well as genetic testing for HD
|
Thomas Bird, MD |
Registration |
|
Activity 3 |
Special Issues – The Prodrome of HD- Describes the early signs of HD before the motor diagnosis
|
Jane Paulsen PhD |
Registration |
|
Activity 4 |
Cognitive Features of HD - How is cognition impacted by HD
|
Jane Paulsen, PhD |
Registration |
|
Activity 5 |
Psychiatric Syndromes in Huntington’s disease – Assessment and Management- Describes the psychiatric syndromes associated with HD and treatment options
|
Adam Rosenblatt, MD, PhD |
Registration |
|
Activity 6 |
Motor Dysfunction and Neurological Care- Addresses the movement disorders associated with HD and treatment options
|
Vicki Wheelock, MD |
Registration |
|
Activity 7 |
Juvenile HD- Describes diagnosis, treatment and care for children affected by juvenile version of HD
|
Martha Nance, MD |
Registration |
|
Activity 8 |
Team Based Care for HD – From the Beginning to the End- Discusses benefits of team based care approach to improving quality of life and overall care of person with HD
|
Martha Nance, MD |
Registration |
|
Activity 9 |
An Overview of Experimental Therapeutics in Huntington’s disease- Describes clinical trial process and currently recruiting trails for HD
|
Kevin Biglan, MD, MPH |
Registration |
|
Activity 10 |
Disability, Advocacy and Conclusions- Explains how physicians can effectively document disability in a person with HD as well as series conclusions
|
Samuel Frank, MD |
Registration |